HIPEC FOR COLORECTAL PERITONEAL CARCINOMATOSIS
CRS + HIPEC EXPLAINED
For selected patients with colorectal cancer that has spread to the peritoneum, cytoreductive surgery combined with heated chemotherapy can extend survival from approximately 13 months to over 22 months β and produce 5-year survival in patients who would have had effectively none.
analyticsAt a Glance
- check_circleVerwaal phase III RCT: median OS 22.3 vs 12.6 months (CRS+HIPEC vs systemic chemo)
- check_circlePRODIGE 7 questioned oxaliplatin HIPEC specifically; mitomycin remains favoured
- check_circlePCI <20 and feasibility of complete cytoreduction are critical eligibility factors
- check_circle5-year survival up to 45% in optimally selected patients (Verwaal long-term data)
Why Colorectal Peritoneal Disease Is Different from Other Metastatic CRC
Approximately 10β15% of colorectal cancer patients develop peritoneal carcinomatosis β either at diagnosis (synchronous) or during follow-up (metachronous). Unlike liver or lung metastases, peritoneal disease responds poorly to systemic chemotherapy and was historically considered terminal. CRS + HIPEC changed that calculus for selected patients.
βPeritoneal carcinomatosis is biologically different from haematogenous metastases β and it responds to a different treatment paradigm. Systemic chemotherapy alone delivers a fraction of the survival benefit that locoregional therapy can.β
Systemic Chemotherapy Alone Is Inadequate
Peritoneal disease responds poorly to FOLFOX, FOLFIRI, and bevacizumab-based systemic therapy compared to liver or lung metastases. Drug delivery to the peritoneal surface is limited by the peritoneal-plasma barrier β the same physiology that justifies direct cavity delivery via HIPEC.
Locoregional Treatment Changes Outcomes
CRS + HIPEC achieves drug concentrations 10β100Γ higher than systemic delivery directly at the peritoneal surface, combined with the cytoreductive surgery that physically removes visible disease. The two-modality approach β surgery + heated chemo β is what makes long-term survival possible.
The Verwaal Trial: Foundational Evidence
The Verwaal phase III randomised trial β conducted at the Netherlands Cancer Institute and published in JCO in 2003 with long-term follow-up in Annals of Oncology in 2008 β established CRS + HIPEC as superior to systemic chemotherapy in colorectal peritoneal disease.
Multi-Centre Dutch Phase III RCT
105 patients with colorectal peritoneal metastases were randomised at the Netherlands Cancer Institute between 1998 and 2001. The trial used the standard care of its era β systemic fluorouracil-leucovorin β as the control arm, reflecting pre-oxaliplatin/irinotecan oncology practice.
Treatment Arms: Systemic Chemo Alone vs CRS + HIPEC
The control arm received 5-FU/leucovorin systemic chemotherapy. The experimental arm received aggressive cytoreductive surgery followed by HIPEC with mitomycin C heated to 41β42Β°C for 90 minutes, followed by the same systemic chemotherapy.
Primary Outcome: Median Overall Survival
Median overall survival improved from 12.6 months in the systemic chemotherapy arm to 22.3 months in the CRS + HIPEC arm β a 9.7-month absolute survival gain. The 5-year overall survival rate was 45% in optimally cytoreduced patients vs 4% with systemic chemo alone.
Long-Term Confirmation (Verwaal 2008)
Eight-year follow-up confirmed sustained survival benefit. Patients who achieved complete cytoreduction (no visible residual disease, CC-0) had the longest survival, demonstrating that surgical completeness β not the HIPEC component alone β is the key prognostic factor.
Trial Outcomes: Verwaal Trial and Long-Term Data
Headline survival results from the foundational Verwaal trial and its long-term follow-up.
Median Overall Survival (Primary Endpoint)
Median time from randomisation to death across both treatment arms.
- Systemic Chemotherapy Alone12.6 mo
- CRS + HIPEC (Mitomycin C)22.3 mo
5-Year Overall Survival
Proportion of patients alive 5 years after randomisation; patients achieving complete cytoreduction (CC-0) had the best outcomes.
- Systemic Chemotherapy Alone4%
- CRS + HIPEC (All Patients)19%
- CRS + HIPEC with Complete Cytoreduction (CC-0)45%
PRODIGE 7 β Oxaliplatin HIPEC (Negative Trial)
265 patients randomised to CRS alone vs CRS + 30-minute oxaliplatin HIPEC. No OS benefit from adding oxaliplatin HIPEC over CRS alone.
- CRS Alone41.7 mo
- CRS + Oxaliplatin HIPEC41.7 mo
The PRODIGE 7 Controversy: What It Did and Did Not Show
The PRODIGE 7 trial (Lancet Oncology, 2021) caused significant reassessment of HIPEC in colorectal cancer. Understanding what the trial did β and did not β disprove is essential to making informed treatment decisions today.
What PRODIGE 7 Showed
PRODIGE 7 randomised 265 patients with CRC peritoneal disease to CRS alone vs CRS + 30-minute oxaliplatin HIPEC. Median OS was identical (41.7 months) in both arms. The trial concluded that adding short-course oxaliplatin HIPEC to optimal CRS did not improve survival.
What PRODIGE 7 Did Not Show
The trial used a 30-minute oxaliplatin protocol β not the 90-minute mitomycin C protocol that produced positive Verwaal results. The control arm received high-quality CRS that itself produced unexpectedly good results (41.7 months OS). The trial does not invalidate mitomycin C HIPEC and does not show that systemic chemotherapy is equivalent to CRS.
Current Clinical Consensus
Most expert centres have moved away from oxaliplatin-based HIPEC for colorectal cancer following PRODIGE 7, but continue to offer mitomycin C-based HIPEC for selected patients. The Verwaal evidence base supporting mitomycin protocols remains the foundation. The role of HIPEC in CRC is more nuanced β and more selective β than it was a decade ago, not abolished.
Prophylactic HIPEC Trials Also Negative
Two additional trials (COLOPEC 2019 and PROPHYLOCHIP 2020) tested whether prophylactic HIPEC at initial CRC surgery prevents peritoneal recurrence in high-risk patients. Both trials were negative. Current practice does not support routine prophylactic HIPEC β only therapeutic HIPEC in patients with established peritoneal disease.
Patient Selection: Who Should Be Offered CRS + HIPEC
Selection criteria distilled from the major trials and modern consensus. Strong candidates have multiple favourable factors.
| Selection Factor | Favourable | Unfavourable |
|---|---|---|
| Peritoneal Cancer Index (PCI) | PCI β€ 20 | PCI > 20 (poor prognosis; HIPEC benefit limited) |
| Extra-Peritoneal Disease | No liver, lung, or distant metastases | Any extra-peritoneal metastases (HIPEC cannot address them) |
| Performance Status | ECOG 0β1 | ECOG 2+ (operative risk too high for benefit) |
| Histology | Well/moderate differentiation; non-signet ring | Signet ring or poorly differentiated (worse prognosis) |
| Synchronous vs Metachronous | Metachronous (later recurrence after primary surgery) | Synchronous with aggressive primary biology |
| Response to Systemic Chemotherapy | Stable or responsive to neoadjuvant FOLFOX/FOLFIRI | Progressive disease on systemic therapy |
| BRAF Mutation Status | BRAF wild-type | BRAF V600E mutation (aggressive biology; benefit reduced) |
| Age and Comorbidities | Age β€ 70; minimal cardiac/pulmonary disease | Significant comorbidity; frailty |
Treatment Pathway for Colorectal Peritoneal Disease
The integrated treatment journey from systemic therapy through CRS + HIPEC to post-operative follow-up.
- 1
Step 1: Systemic Chemotherapy (Neoadjuvant)
3β6 cycles of FOLFOX or FOLFIRI Β± bevacizumab. This tests tumour biology (response to systemic therapy is prognostic), controls extra-peritoneal disease if any, and may reduce PCI prior to surgery.
- 2
Step 2: Restaging and CRS + HIPEC Assessment
CT/MRI restaging confirms peritoneum-confined disease. Diagnostic laparoscopy may be used to estimate intraoperative PCI before committing to laparotomy. Multi-disciplinary review confirms candidacy.
- 3
Step 3: Cytoreductive Surgery + HIPEC
Single OR session: complete peritonectomy and resection of all visible disease, followed by HIPEC with mitomycin C at 41β42Β°C for 90 minutes. The procedure lasts 8β14 hours total.
- 4
Step 4: Hospital Recovery
1β3 days ICU; 7β14 days total inpatient stay. Pain management, nutrition support, and surveillance for surgical complications (anastomotic leak, ileus, infection).
- 5
Step 5: Adjuvant Chemotherapy and Surveillance
After surgical recovery (4β8 weeks), most patients complete adjuvant systemic chemotherapy. Long-term surveillance with CEA monitoring and CT imaging every 3β6 months for 2 years, then annually.
Related Treatments & Resources
Explore the full hyperthermia knowledge base.
- HIPEC: What Is Hyperthermic Intraperitoneal Chemotherapy and Who Is a Candidate?
- How Heat Makes Chemotherapy Work Better: Drug-Heat Interactions
- HIPEC for Ovarian Cancer: The OVHIPEC Trial
- HIPEC for Gastric Cancer Peritoneal Disease β China Programme
- Hyperthermia Therapy in China
- HIPEC for Peritoneal Cancer β Full Treatment Page
Frequently Asked Questions
Common questions about CRS + HIPEC for colorectal peritoneal carcinomatosis.
About the Evidence
Did PRODIGE 7 disprove HIPEC for colorectal cancer?
No. PRODIGE 7 specifically disproved 30-minute oxaliplatin HIPEC added to optimal CRS. It did not test mitomycin C HIPEC (the Verwaal protocol). It did not compare HIPEC against systemic chemotherapy alone. Mitomycin-based CRS + HIPEC remains supported by the Verwaal evidence and is still offered at major centres for selected patients.
What drug should be used for HIPEC in colorectal cancer today?
Most expert centres have moved away from oxaliplatin and toward mitomycin C following PRODIGE 7. Mitomycin C at 35 mg/mΒ² heated to 41β42Β°C for 90 minutes is the most commonly used protocol. Some centres still use modified oxaliplatin protocols at longer durations, and ongoing trials are exploring optimised regimens.
Should I have prophylactic HIPEC if I am at high risk of peritoneal recurrence?
Current evidence does not support prophylactic HIPEC. Both COLOPEC (2019) and PROPHYLOCHIP (2020) randomised trials showed no benefit from prophylactic HIPEC in high-risk CRC patients. Surveillance is the current standard; therapeutic HIPEC is reserved for established peritoneal disease.
About Eligibility and Access
I have colorectal cancer with peritoneal mets β am I a candidate?
Candidacy depends on PCI score, absence of extra-peritoneal disease, performance status, tumour biology, and the feasibility of complete cytoreduction. The only way to definitively assess candidacy is specialist surgical oncology review of imaging and treatment history. CancerFax can coordinate this evaluation with experienced HIPEC centres.
I have peritoneal AND liver metastases β can I still have HIPEC?
Generally no, but with nuances. Liver metastases are an exclusion in most HIPEC protocols. However, selected patients with limited liver disease that can also be resected simultaneously may be candidates for combined liver resection + CRS + HIPEC at very experienced centres. This is a complex decision requiring expert multi-disciplinary review.
What are my outcomes likely to be?
Outcomes depend heavily on the completeness of cytoreduction (CC-0 vs CC-1 vs CC-2), PCI score, and tumour biology. Patients achieving CC-0 with low PCI have 5-year survival up to 45%. Patients with PCI > 20 or incomplete cytoreduction have substantially worse outcomes and may be better served by systemic therapy alone.
Where can I access CRS + HIPEC for CRC?
CRS + HIPEC requires a high-volume specialist centre. Major programmes exist in Europe (Netherlands, France, Germany, Italy), the US (MD Anderson, Memorial Sloan Kettering, others), China (multiple major centres), and India. CancerFax coordinates with experienced centres in all these regions.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Am I a Candidate for CRS + HIPEC?
Upload your imaging, pathology, and treatment history. Our oncology team will coordinate a specialist surgical oncology review to assess your peritoneal cancer index, evaluate HIPEC eligibility, and identify the right specialist centre for your case.
This content is for informational purposes only and does not constitute medical advice. HIPEC eligibility decisions must be made by a specialist surgical oncology team after complete evaluation.